MedTrace Logo

Study of GLS-010 Injection in Patients With Recurrent or Metastatic Cervical Cancer

NCT03972722 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 89

Last updated 2019-06-05

No results posted yet for this study

Summary

Patients with recurrent or metastatic cervical cancer，and will be treated with GLS-010.

Conditions

Interventions

DRUG

GLS-010

Patients will be given 240mg GLS-010 every treatment.

Sponsors & Collaborators

  • Guangzhou Gloria Biosciences Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiaohua Wu, MD · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-15
Primary Completion
2022-05-15
Completion
2023-05-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03972722 on ClinicalTrials.gov